capecitabine + lapatinib + trastuzumab

This is a combination therapy consisting of three agents—capecitabine, lapatinib, and trastuzumab—used primarily in the treatment of HER2-positive metastatic breast cancer (MBC), especially after progression on prior trastuzumab-containing regimens. - **Capecitabine** is an oral prodrug that is converted to 5-fluorouracil (5-FU) in the body and acts as an antimetabolite chemotherapeutic agent by inhibiting DNA synthesis. - **Lapatinib** is an orally active small molecule tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2), blocking downstream signaling pathways involved in cell proliferation and survival. - **Trastuzumab** is a monoclonal antibody that binds to the extracellular domain of HER2, inhibiting its signaling and mediating antibody-dependent cellular cytotoxicity. The rationale for this triplet combination lies in maximizing HER2 blockade through dual anti-HER2 targeting with both lapatinib (intracellular inhibition) and trastuzumab (extracellular inhibition), combined with chemotherapy for cytotoxic effect. Clinical studies have shown this regimen to be effective and generally well-tolerated in patients with advanced or metastatic HER2-positive breast cancer who have progressed on previous therapies[5][6]. The most common serious adverse events include neutropenia, leukopenia, diarrhea, palmar–plantar erythrodysesthesia syndrome, and anemia[5].

Other names

CLT regimenTLC regimen